BioCentury
ARTICLE | Clinical News

Argos falls on Phase IIb miss in HIV

January 9, 2015 8:00 AM UTC

Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy interruption vs. placebo in a Phase IIb trial to treat HIV.

AGS-004 is an autologous dendritic cell immunotherapy transfected with the patient's viral RNA antigens. ...